Study is the first to map variations in gene regulation at the cell type level throughout the lung
Author Archive: AZBio
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer
Results indicate potential of a minimally invasive screening tool to detect most common form of Esophageal Cancer, a highly treatable cancer if caught early Continue reading
UArizona scientists pinpoint anorexia’s neurologic origins
The discovery, led by Haijiang Cai, an associate professor in the Department of Neuroscience, was observed in mice, but the findings could lead to human drug treatments.Continue reading
Match Day reveals next paths in future physicians’ careers
Fourth-year students at the College of Medicine – Tucson and the College of Medicine – Phoenix learned where their journey to become physicians will take them next.Continue reading
AZBio Members – Apply before April 19th for MTC Flex Pass Savings
The Medtech Conference, October 15-17, 2024 in Toronto, Canada features the new Medtech campus, thousands of medtech professionals and innovative companies, a curated cross-cutting education program, invaluable access to key decision makers, next-level technology and efficient networking. Join us to gain insights, connections, and advancements to propel your company forward in the dynamic medical technology landscape.Continue reading
Breakthrough Results of NIH-Sponsored Study of Syn-One Test® as a Skin-Based Diagnostic Tool for Parkinson’s Disease and Related Disorders Published in the Journal of the American Medical Association
- Study demonstrates alpha-synuclein biomarker can be detected in 93-100% of patients with clinically defined pathologies using simple skin biopsy procedure
- Syn-One Test addresses key unmet needs by supporting accurate diagnoses for patients and serving as a reliable biomarker for clinical trials
Jennifer Kehlet Barton embarks on tenure as president of SPIE, bolstering University of Arizona’s global impact
As the BIO5 Institute director assumes her presidency of SPIE, the international society for optics and photonics in 2024, she propels the international society for optics and photonics into new frontiers and underscores her role as a leader in cutting-edge research and innovation while representing UArizona.Continue reading
Ranking Member Cassidy Seeks Information from Stakeholders on Regulation of Clinical Tests
WASHINGTON – Today, U.S. Senator Bill Cassidy, M.D. (R-LA), ranking member of the Senate Health, Education, Labor, and Pensions (HELP) Committee, requested information from stakeholders on ways to improve regulation of clinical tests in the United States. Continue reading
Chairs Rodgers and Guthrie Announce Health Subcommittee Hearing on Regulation of Diagnostic Tests
The Energy and Commerce Health Subcommittee will hold a hearing, “Evaluating Approaches to Diagnostic Test Regulation and the Impact of FDA’s Proposed Rule” on Thursday, March 21 at 10:00 AM EDT.
The E&C hearing will be live streamed starting at 7 AM AZ/PDT via https://energycommerce.house.gov/Continue reading
U.S. FDA Approves Bristol Myers Squibb’s Breyanzi ® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
PRINCETON, N.J.–Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). In R/R CLL or SLL, Breyanzi is delivered through a treatment process which culminates in a one-time infusion* with a single dose containing 90 to 110 x 106 CAR-positive viable T cells.Continue reading